Skip to search formSkip to main contentSkip to account menu

IMMU-106

Known as: monoclonal antibody IMMU-106 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

veltuzumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Monoclonal Antibodies in the Treatment of Non-Hodgkin’s Lymphoma
Antibody-based therapeutic approaches have had a significant impact in the treatment of non-Hodgkin’s lymphoma (NHL). Rituximab’s… 
Review
2011
Review
2011
New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid Malignancies
Over the last few years, new generations of anti-CD20 monoclonal antibodies (mAbs) have been developed for potential benefits… 
Review
2009
Review
2009
Monoclonal antibodies in the treatment of systemic lupus erythematosus.
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by B cell hyperactivity and defective T-cell function… 
2007
2007
Low doses of humanized anti-CD20 antibody, IMMU-106 (hA20), in refractory or recurrent NHL: Phase I/II results
8032 Background: An open-label, multicenter study has shown that the humanized anti-CD20 antibody, IMMU-106 (hA20), which has… 
2007
2007
Hapten-Peptide Induces Apoptosis in Human Non ^ Hodgkin Lymphoma Cell Lines Targeted by Anti-CD 20 Anti-Hapten Bispecific Antibodies
Purpose:Bispecific antibody (bsMAb) pretargeting procedures use divalent hapten-peptides to stabilize the binding of the hapten… 
2007
2007
Preliminary results of a phase I/II study of the humanized anti-CD20 antibody IMMU-106 (hA20) in patients with relapsed non-Hodgkin lymphoma
2006
2006
Phase I/II results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in NHL.
7530 Background: The humanized anti-CD20 antibody, IMMU-106 (hA20), has similar murine CDRs to rituximab, but the remaining… 
2006
2006
Rituximab-Relapsing Patients with Non-Hodgkins Lymphoma Respond Even at Lower Doses of Humanized Anti-CD20 Antibody, IMMU-106 ( hA 20): Phase I/II Results.
Background: An open-label, multicenter, dose-escalation study in patients with recurrent NHL was initially undertaken to… 
2006
2006
A new method of constructing CD20/CD22 bispecfic antibody fusion proteins with improved direct lymphoma cytotoxicity compared to rituximab.
2536 Background: Anti-CD20 and anti-CD22 monoclonal antibodies (MAbs) have been shown to have antitumor activity in non-Hodgkin's… 
2005
2005
Initial Safety and Efficacy Results of a Second-Generation Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Non-Hodgkin’s Lymphoma.
Background. Infusion reactions, prolonged infusion times and immunogenicity of the chimeric anti-CD20 antibody, rituximab, may in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)